Mladen Maksic, Tijana Veljković, M. Cvetković, Marija Markovic, Saša Perić, O. Marinković, N. Zdravković
{"title":"Fecal calprotectin: A marker of Crohn's disease activity","authors":"Mladen Maksic, Tijana Veljković, M. Cvetković, Marija Markovic, Saša Perić, O. Marinković, N. Zdravković","doi":"10.5937/afmnai40-39534","DOIUrl":null,"url":null,"abstract":"Introduction. Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with periods of remission and exacerbation. Numerous studies have been conducted in order to identify the ideal marker when it comes to the inflammatory bowel diseases. In the literature, fecal calprotectin is mentioned as a marker of inflammation. Elevated levels of calprotectin can be detected in stool and they indicate the migration of neutrophils to the intestinal mucosa that occurs with intestinal inflammation. The aim. The main goal of this study was to examine the concentration of fecal calprotectin and CRP depending on the clinical, endoscopic and histological characteristics of patients with Crohn's disease and whether there is a correlation of these markers with disease activity. Methods. The research was conducted in the period from January 2015 to January 2016. The study included subjects who had been diagnosed with Crohn's disease. The study involved 45 respondents, aged 20 - 58 years. All subjects included in the study underwent a colonoscopic examination with biopsy and pathohistological analysis. Fecal calprotectin was determined in one stool sample in all subjects, and that was done quantitatively by a commercial ELISA assay. Determination of serum CRP concentrations was performed in the Central Biochemical Laboratory by standard methods. Results. Fecal concentrations of calprotectin are elevated in all three forms of the disease, while they are significantly higher in moderately severe (545 vs. 218, p ˂ 0.001) and severe forms of the disease (1000 vs. 218, p ˂ 0.001) compared to the mild form. Fecal concentrations of calprotectin are significantly higher at endoscopic grade 3 compared to the other three endoscopic grades (765.3 vs. 314, p ˂ 0.001), (765.3 vs. 392.8, p ˂ 0.001), (765.3 vs. 448.2, p ˂ 0.001). Fecal concentrations of calprotectin are significantly higher in extensive pathological findings compared to normal epithelial surface (1000 vs. 21, p ˂ 0.001) as well as in extensive pathological findings compared to focal pathological findings (1000 vs. 309, p ˂ 0.001). Conclusion. The more severe form of clinical disease activity is accompanied by higher fecal values of calprotectin and higher endoscopic grade, and a more severe histological grade of disease is accompanied by higher fecal values of calprotectin.","PeriodicalId":7132,"journal":{"name":"Acta Facultatis Medicae Naissensis","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Facultatis Medicae Naissensis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/afmnai40-39534","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction. Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with periods of remission and exacerbation. Numerous studies have been conducted in order to identify the ideal marker when it comes to the inflammatory bowel diseases. In the literature, fecal calprotectin is mentioned as a marker of inflammation. Elevated levels of calprotectin can be detected in stool and they indicate the migration of neutrophils to the intestinal mucosa that occurs with intestinal inflammation. The aim. The main goal of this study was to examine the concentration of fecal calprotectin and CRP depending on the clinical, endoscopic and histological characteristics of patients with Crohn's disease and whether there is a correlation of these markers with disease activity. Methods. The research was conducted in the period from January 2015 to January 2016. The study included subjects who had been diagnosed with Crohn's disease. The study involved 45 respondents, aged 20 - 58 years. All subjects included in the study underwent a colonoscopic examination with biopsy and pathohistological analysis. Fecal calprotectin was determined in one stool sample in all subjects, and that was done quantitatively by a commercial ELISA assay. Determination of serum CRP concentrations was performed in the Central Biochemical Laboratory by standard methods. Results. Fecal concentrations of calprotectin are elevated in all three forms of the disease, while they are significantly higher in moderately severe (545 vs. 218, p ˂ 0.001) and severe forms of the disease (1000 vs. 218, p ˂ 0.001) compared to the mild form. Fecal concentrations of calprotectin are significantly higher at endoscopic grade 3 compared to the other three endoscopic grades (765.3 vs. 314, p ˂ 0.001), (765.3 vs. 392.8, p ˂ 0.001), (765.3 vs. 448.2, p ˂ 0.001). Fecal concentrations of calprotectin are significantly higher in extensive pathological findings compared to normal epithelial surface (1000 vs. 21, p ˂ 0.001) as well as in extensive pathological findings compared to focal pathological findings (1000 vs. 309, p ˂ 0.001). Conclusion. The more severe form of clinical disease activity is accompanied by higher fecal values of calprotectin and higher endoscopic grade, and a more severe histological grade of disease is accompanied by higher fecal values of calprotectin.
介绍。克罗恩病(CD)是一种慢性炎症性肠病(IBD),有缓解期和加重期。为了确定炎症性肠病的理想标志物,已经进行了大量的研究。在文献中,粪便钙保护蛋白被认为是炎症的标志。在粪便中可以检测到钙保护蛋白水平升高,这表明中性粒细胞迁移到肠道黏膜,发生肠道炎症。的目标。本研究的主要目的是检查粪便钙保护蛋白和CRP的浓度取决于克罗恩病患者的临床、内镜和组织学特征,以及这些标志物与疾病活动性是否存在相关性。方法。研究时间为2015年1月至2016年1月。该研究包括被诊断患有克罗恩病的受试者。这项研究涉及45名年龄在20 - 58岁之间的受访者。所有纳入研究的受试者均进行了结肠镜检查、活检和病理组织学分析。在所有受试者的一个粪便样本中测定粪钙保护蛋白,并通过商业ELISA定量测定。血清CRP浓度测定在中央生化实验室按标准方法进行。结果。在所有三种形式的疾病中,粪便钙保护蛋白浓度都升高,而在中重度(545 vs. 218, p小于0.001)和重度(1000 vs. 218, p小于0.001)的疾病中,粪便钙保护蛋白浓度明显高于轻度形式。内镜下3级的粪便钙保护蛋白浓度明显高于其他3级(765.3 vs. 314, p小于0.001),(765.3 vs. 392.8, p小于0.001),(765.3 vs. 448.2, p小于0.001)。与正常上皮表面相比,广泛病理结果中的粪便钙保护蛋白浓度明显更高(1000 vs. 21, p小于0.001),广泛病理结果中的粪便钙保护蛋白浓度也明显高于局灶性病理结果(1000 vs. 309, p小于0.001)。结论。更严重的临床疾病活动形式伴随着更高的钙保护蛋白粪便值和更高的内镜分级,更严重的疾病组织学分级伴随着更高的钙保护蛋白粪便值。